Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KIF15 | Q9NS87 | 1/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234996 | 0.89 | DPP4 (0.40) | TP53 | |
| SCHEMBL5321491 | 0.89 | RAB9A (0.34) | MDM2MEN1KMT2A | |
| SCHEMBL5232834 | 0.86 | CDC7 (0.37) | LMNACDC7DBF4TSHRMEN1 | |
| SCHEMBL27599399 | 0.85 | ACHE (0.34) | MDM2KMT2AMDM4TP53 | |
| SCHEMBL6112299 | 0.83 | RAB9A (0.33) | MEN1KMT2ATP53XIAP | |
| Hydrochloric Acid SCHEMBL5232287 | 0.81 | DPP4 (0.43) | LMNACDC7DBF4 | |
| SCHEMBL5234400 | 0.79 | DPP4 (0.39) | MEN1KMT2ATP53 | |
| SCHEMBL5231027 | 0.79 | TARBP2 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL5317843 | 0.78 | DPP4 (0.39) | — | |
| SCHEMBL6112296 | 0.78 | RAB9A (0.34) | MDM2MEN1KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | LMNA 1764/4885CDC7 4413/4885DBF4 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.